Linked Life Data

11841931

Source:http://linkedlifedata.com/resource/pubmed/id/11841931

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2002-2-13
pubmed:abstractText
The oral, tumour-selective fluoropyrimidine capecitabine represents a major new strategy for the treatment of colorectal cancer. Pooled results from two large, multicentre, open-label, phase III studies comparing oral capecitabine (1250 mg/m2 twice daily for 14 days every 3 weeks) with the Mayo Clinic regimen (5-fluorouracil [5-FU] 425 mg/m2 plus leucovorin 20 mg/m2 days 1-5, every 4 weeks) provide information on over 1200 patients receiving first-line chemotherapy for metastatic colorectal cancer. Analysis of all randomised patients demonstrated a significantly superior overall response rate as assessed by the investigator for capecitabine compared with 5-FU/leucovorin (25.7% versus 16.7%, P<0.0002), reinforcing the individual trial results. Median time to disease progression, overall survival and duration of response were equivalent in the two treatment groups. Furthermore, capecitabine showed a superior safety profile compared with 5-FU/leucovorin, with a significantly lower incidence (P<0.001) of diarrhoea, stomatitis, nausea and alopecia, together with a reduced treatment-related hospitalisation rate. In addition, the incidence of neutropenic fever/sepsis was significantly lower in patients receiving capecitabine.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
38 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
15-20
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:11841931-Adult, pubmed-meshheading:11841931-Aged, pubmed-meshheading:11841931-Aged, 80 and over, pubmed-meshheading:11841931-Antimetabolites, Antineoplastic, pubmed-meshheading:11841931-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11841931-Clinical Trials, Phase III as Topic, pubmed-meshheading:11841931-Colorectal Neoplasms, pubmed-meshheading:11841931-Deoxycytidine, pubmed-meshheading:11841931-Female, pubmed-meshheading:11841931-Fluorouracil, pubmed-meshheading:11841931-Humans, pubmed-meshheading:11841931-Infusions, Intravenous, pubmed-meshheading:11841931-Leucovorin, pubmed-meshheading:11841931-Male, pubmed-meshheading:11841931-Middle Aged, pubmed-meshheading:11841931-Multicenter Studies as Topic, pubmed-meshheading:11841931-Randomized Controlled Trials as Topic
pubmed:year
2002
pubmed:articleTitle
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
pubmed:affiliation
Alexander Stone Building, CRC Department of Medical Oncology, Switchback Road, Garscube Estate, Bearsden, Glasgow G61 1BD, UK. c.twelves@beatson.gla.ac.uk
pubmed:publicationType
Journal Article, Comparative Study